Welcome to our dedicated page for Nanobiotix news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix stock.
Nanobiotix S.A. develops nanotechnology-based therapeutic platforms for cancer and other major diseases as a late-stage clinical biotechnology company. Its news commonly centers on JNJ-1900 (NBTXR3), a hafnium oxide nanoparticle radioenhancer administered by intratumoral injection and activated by radiotherapy, including head and neck cancer and lung cancer development updates, clinical data presentations, and regulatory communications.
Company updates also cover the Nanoprimer platform for bioavailability and biodistribution, preclinical work with lipid nanoparticle-delivered therapies, collaborations with Johnson & Johnson, Janssen and MD Anderson, periodic operating and financial results, and recurring disclosures of share capital and voting rights for its Euronext Paris and Nasdaq-listed securities.
Nanobiotix (NASDAQ: NBTX) announces it will release its full-year financial results for 2022 on April 24, 2023, after the US market closes. A conference call is scheduled for April 25, 2023, at 2:00 PM CEST/8:00 AM EDT, where CEO Laurent Levy and CFO Bart van Rhijn will discuss year-end results and current business activities. The company is focused on physics-based therapeutic approaches in oncology and has achieved market authorization for its lead product, NBTXR3, in Europe for treating soft tissue sarcoma. Founded in 2003 and headquartered in Paris, Nanobiotix is publicly traded on Euronext and NASDAQ, reflecting its commitment to innovative cancer treatments.
Nanobiotix announced on April 11, 2023, its monthly update regarding the total number of voting rights and shares outstanding. For March 31, 2023, the company reported 34,875,872 shares outstanding and 36,634,849 total voting rights, with 36,612,731 of them exercisable. This disclosure complies with French regulations aimed at ensuring transparency in public companies. Nanobiotix is engaged in pioneering therapeutic approaches for treating solid tumors, notably through its lead product, NBTXR3, targeting head and neck cancers. Further information about the company and its innovations can be found on their official website.
Nanobiotix (NASDAQ: NBTX), a clinical biotechnology company focused on cancer treatment, has announced a postponement of its full-year 2022 financial results originally set for March 28, 2023, and its conference call on March 29, 2023. The decision is made to provide additional time for year-end closing procedures. The company will issue a future press release to update stakeholders on the new schedule. Nanobiotix is recognized for its innovative physics-based therapeutic approaches and has developed NBTXR3, which has received market approval in Europe for treating soft tissue sarcoma.
Nanobiotix, a late-stage clinical biotechnology company, will provide an operational update and financial results for the fiscal year ending December 31, 2022, on March 28, 2023. A conference call will follow on March 29, 2023, at 2:00 PM CET/8:00 AM EDT, led by CEO Laurent Levy and CFO Bart Van Rhijn. The focus will be on year-end results and business updates. Nanobiotix's lead product, NBTXR3, a potential first-in-class oncology treatment, is being evaluated for locally advanced head and neck cancer with favorable early-phase data. The company has strategic collaborations to expand product development across tumor types.
Nanobiotix has released its latest update on the total number of voting rights and shares as of January 31, 2023. The total number of shares outstanding is 34,875,872, with 36,286,976 theoretical voting rights and 36,264,858 exercisable voting rights. This report aligns with the French Commercial Code requirements for transparency. Nanobiotix's lead product candidate, NBTXR3, aims to enhance treatment outcomes for solid tumors, particularly in head and neck cancers. For further details, visit their website at www.nanobiotix.com.
Nanobiotix disclosed key shareholder information as of December 31, 2022. The total number of shares outstanding was 34,875,872, while total voting rights were 36,287,449 (theoretical) and 36,265,331 (exercisable). The company announced the termination of its liquidity contract with Gilbert Dupont, effective December 20, 2022. This follows a prior announcement on December 21, 2022. Going forward, Nanobiotix will provide monthly updates on voting rights and shares as required by French regulations.
Nanobiotix has announced that the pivotal phase 3 NANORAY-312 study for NBTXR3 has activated sites across 80 locations globally, including the US, Europe, and Asia. This trial evaluates NBTXR3, a radioenhancer, for elderly patients with locally advanced head and neck squamous cell carcinoma who cannot use platinum-based chemotherapy. The trial, which aims to enroll 500 patients, expects a futility analysis in the second half of 2023 and interim results in 2024. The company believes the data from previous studies support the potential of NBTXR3.
Nanobiotix (NASDAQ: NBTX) has announced the termination of its liquidity contract with Gilbert Dupont, effective December 20, 2022. This decision follows the review of the liquidity account, which held 22,118 shares and €71,489.96 in cash at the time of termination. The company reported a trading volume of 303,404 shares on the buy side and 306,992 shares on the sell side between July and December 2022, indicating active market participation. Despite ending this contract, Nanobiotix continues its focus on developing its lead product, NBTXR3, which has received market authorization in Europe.
Nanobiotix announced its shareholding structure as of November 30, 2022, revealing a total of 34,875,872 shares outstanding. The total number of theoretical voting rights stands at 36,286,699, while the exercisable voting rights are 36,269,556. This disclosure is in compliance with French financial regulations aimed at ensuring transparency in corporate governance. Nanobiotix continues to advance its pipeline of innovative therapeutic options for cancer treatment, leveraging its patented nanoparticle technology.
NANOBIOTIX, a late-stage clinical biotechnology company, announced that its co-founder Laurent Levy and CFO Bart Van Rhijn will participate in a virtual fireside chat at the 5th annual Evercore ISI HealthCONx Conference on December 1, 2022, at 9:15 AM ET / 3:15 PM CET. The chat will be available live on the company's website and archived for 90 days. NANOBIOTIX focuses on enhancing cancer treatment outcomes through its innovative nanoparticle platform, especially targeting head and neck cancers.